6-bromomethyl-benzo[1,2,5]oxadiazole-1-oxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 英文名称: 6-bromomethyl-benzo[1,2,5]oxadiazole-1-oxide
• 英文别名: 6-(Bromomethyl)Benzo[C][1,2,5]Oxadiazole1-Oxide；5-(bromomethyl)-3-oxido-2,1,3-benzoxadiazol-3-ium
• 化学式: C₇H₅BrN₂O₂
• 分子量: 229.033
• InChiKey: PPJXFQORUAVJNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  51.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  diclofenac sodium 、 6-bromomethyl-benzo[1,2,5]oxadiazole-1-oxide 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以89%的产率得到[2-(2,6-dichlorophenylamino)-phenyl]-acetic acid 1-oxy-benzo[1,2,5]oxadiazol-6-ylmethyl ester
  参考文献：
  名称：

  [EN] DRUGS DERIVED FROM DICLOFENAC CONTAINING NO-DONOR HETEROCYCLES, COMPOSITION AND METHOD OF INFLAMMATION TREATMENT
  [FR] MEDICAMENTS DERIVES DU DICLOFENAC, CONTENANT DES HETEROCYCLES DONNEURS DE NO, COMPOSITION ET METHODE DE TRAITEMENT DES INFLAMMATIONS

  摘要：

  本发明涉及与制药物质双氯芬酸有关的药物，相对于该化学式。该发明还涉及一种制药组合物，其中包括所述药物和药学上适当的载体。还描述了一种通过在患有胃部问题或接受长期治疗的患者中施用新药物来治疗炎症的方法。

  公开号：

  WO2006042387A1
• 作为产物：
  描述：

  6-methylbenzofuroxan 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 5.0h， 以85%的产率得到6-bromomethyl-benzo[1,2,5]oxadiazole-1-oxide
  参考文献：
  名称：

  [EN] DRUGS DERIVED FROM DICLOFENAC CONTAINING NO-DONOR HETEROCYCLES, COMPOSITION AND METHOD OF INFLAMMATION TREATMENT
  [FR] MEDICAMENTS DERIVES DU DICLOFENAC, CONTENANT DES HETEROCYCLES DONNEURS DE NO, COMPOSITION ET METHODE DE TRAITEMENT DES INFLAMMATIONS

  摘要：

  本发明涉及与制药物质双氯芬酸有关的药物，相对于该化学式。该发明还涉及一种制药组合物，其中包括所述药物和药学上适当的载体。还描述了一种通过在患有胃部问题或接受长期治疗的患者中施用新药物来治疗炎症的方法。

  公开号：

  WO2006042387A1

文献信息

• Naftifine-analogues as anti-Trypanosoma cruzi agents
  作者：Alejandra Gerpe、Lucía Boiani、Paola Hernández、Maximiliano Sortino、Susana Zacchino、Mercedes González、Hugo Cerecetto

  DOI：10.1016/j.ejmech.2010.01.052

  日期：2010.6

  oxidative stress. Here, we describe the synthesis and the activity of new containing bioactive-heterocycles analogues of naftifine as potential T. cruzi membrane sterol biosynthesis inhibitors. Benzimidazole 1,3-dioxides (11 and 13) and quinoxaline 1,4-dioxides (22 and 23) displayed excellent parasite/mammal selectivity indexes. Analysis of the free sterols from parasite incubated with the compounds

  恰加斯病是中美洲和南美洲的一个相关健康问题。一线治疗是尼呋替莫克斯和苯并咪唑，它们有很多缺点，需要快速产生治疗选择。基于我们对氮杂硫杂杂环化合物作为抗克氏锥虫的研究，我们确定了可通过氧化应激起作用的药效基团。在这里，我们描述了萘菲芬新的生物活性杂环类似物作为潜在的克鲁斯膜固醇生物合成抑制剂的合成和活性。苯并咪唑1,3-二氧化物（11和13）和喹喔啉1,4-二氧化物（22和23））显示出极好的寄生虫/哺乳动物选择性指数。分析与化合物孵育的寄生虫产生的游离固醇，表明它们中的任何一个都能积聚角鲨烯，这表明在抗T. cruzi的作用机理中不涉及对固醇生物合成的抑制。还测试了一些衍生物作为抗真菌剂。在本工作中获得的结果为这些传染病打开了新化合物的潜在治疗可能性。
• New Limonene-Hybrid Derivatives with Anti-T. cruzi Activity
  作者：G. Alvarez、A. Gerpe、D. Benitez、F. Garibotto、S. Zacchino、C. S. Graebin、R. Gomes da Rosa、V. L. Eifler-Lima、M. Gonzalez、H. Cerecetto

  DOI：10.2174/157018010791306524

  日期：2010.7.1

  The development of hybrid compounds containing limonene- and recognized anti-T. cruzi-heterocycleframeworks is described. The six new compounds displayed broad antitrypanosomal activities having 5-nitrofuran and 5- nitroindazole derivatives, the best profiles. In addition, a 5-nitroindazole derivative evaluated against a panel of fungi exhibited relevant activities. Knowing that free-radical-production operates as one of the mechanisms of action on these heterocycles, we studied a potential extra-mechanism, membrane-sterols changes. Non-relevant T. cruzi squalene accumulation was observed for any of the tested hybrid-limonene derivatives.

  含有柠檬烯和公认的抗 T 的杂化化合物的开发。描述了 cruzi-heterocycleframeworks。这六种新化合物表现出广泛的抗锥虫活性，其中 5-硝基呋喃和 5-硝基吲唑衍生物表现最好。此外，对一组真菌进行评估的 5-硝基吲唑衍生物表现出相关活性。知道自由基产生是这些杂环化合物的作用机制之一，我们研究了一种潜在的额外机制，即膜甾醇的变化。对于任何测试的混合柠檬烯衍生物都观察到非相关的克氏锥虫角鲨烯积累。
• New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle
  作者：Williams Porcal、Paola Hernández、Lucía Boiani、Mariana Boiani、Ana Ferreira、Agustina Chidichimo、Juan J. Cazzulo、Claudio Olea-Azar、Mercedes González、Hugo Cerecetto

  DOI：10.1016/j.bmc.2008.05.038

  日期：2008.7

  Hybrid compounds containing hydrazones and benzofuroxan pharmacophores were designed as potential Trypanosoma cruzi-enzyme inhibitors. The majority of the designed compounds was successfully synthesized and biologically evaluated displaying remarkable in vitro activity against different strains of T. cruzi. Unspecific cytotoxicity was evaluated using mouse macrophages, displaying isothiosemicarbazone 10 and thiosemicarbazone 12 selectivity indexes (macrophage/parasite) of 21 and 27, respectively. In addition, the mode of anti-trypanosomal action of the derivatives was investigated. Some of these derivatives were moderate inhibitors of cysteinyl active site enzymes of T. cruzi, cruzipain and trypanothione reductase. ESR experiments using T. cruzi microsomal fraction suggest that the main mechanism of action of the trypanocidal effects is the production of oxidative stress into the parasite. (c) 2008 Elsevier Ltd. All rights reserved.
• [EN] DRUGS DERIVED FROM DICLOFENAC CONTAINING NO-DONOR HETEROCYCLES, COMPOSITION AND METHOD OF INFLAMMATION TREATMENT<br/>[FR] MEDICAMENTS DERIVES DU DICLOFENAC, CONTENANT DES HETEROCYCLES DONNEURS DE NO, COMPOSITION ET METHODE DE TRAITEMENT DES INFLAMMATIONS
  申请人：CMAX OTIMIZACAO DE RESULTADOS

  公开号：WO2006042387A1

  公开（公告）日：2006-04-27

  The present invention refers to drugs resulting from the pharmaceutical substance diclofenac, relative to the formula. The invention further refers to a pharmaceutical composition, which involves the said drugs and a pharmaceutically adequate vehicle. It is also described a method for the treatment of inflammation through the administration of the new drugs in patients with gastric problems or subjected to long-term treatments.

  本发明涉及与制药物质双氯芬酸有关的药物，相对于该化学式。该发明还涉及一种制药组合物，其中包括所述药物和药学上适当的载体。还描述了一种通过在患有胃部问题或接受长期治疗的患者中施用新药物来治疗炎症的方法。